CytomX Therapeutics, Inc.

CytomX Therapeutics Misses on EPS, Stock Up 3.82%

CytomX Therapeutics reported a loss per share that was slightly below expectations, but the stock reacted positively, rising by 3.82%. This increase may reflect investor optimism despite the earnings miss, as the market often looks beyond short-term results. However, without additional guidance or commentary from management, the outlook remains uncertain.